Special ArticleRadiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
Cited by (0)
Presented at the 57th ASTRO Annual Meeting, October 18-21, 2015, San Antonio, TX.
Conflicts of interest: Before initiating work on this guideline, all panelists completed disclosure statements and pertinent disclosures are published within this report. Where potential conflicts are detected, remedial measures to address them are taken and noted here.
Dr Kirkpatrick receives research funding, honoraria, and travel expenses from Varian; is a partner in ClearSight Radiotherapy Products; and received previous research funding from Genentech. Dr Fiveash receives honoraria, travel expenses, and research funding from Varian. Dr Shig serves on an advisory board for Genentech and received previous honoraria and travel expenses from Merck. Dr Koay receives research funding from Phillips and has a pending patent on quantitative pancreatic image analysis. Dr Lutz had previous stock in Tosk and Oculus. Dr Vogelbaum is a consultant for NeuralStem and has stock options, royalties, and patent licensing and copyright fees from Infuseon. Dr Reardon serves on advisory boards for Roche/Genentech, EMD Serono, Novartis, Amgen, Abbvie, Bristol-Myers Squibb, Cavion, Celldex, Juno Pharmaceuticals, Momenta Pharmaceuticals, Novocure, Oxigene, Regeneron, and Stemline; served on a previous advisory board for Apogenix; is on speaker bureaus for Merck/Scherin and Roche/Genentech; and receives research funding from Celldex, Inovio, and Midatech. Dr Wen is on advisory boards for Roche/Genentech, Novartis, Regeneron, Monteris, and Cavion; is a speaker for Merck; is steering committee chair for Vascular Biogenics trial; and was previously on advisory boards for Abbvie, Cubist, Foundation Medicine, Merck, and Midatech. Dr Chang receives honoraria from Abbvie BrainLab, and Elekta.
The panel chairs and American Society for Radiation Oncology Guidelines Subcommittee reviewed these disclosures and took measures to mitigate the impact of potential conflicts. Because of relationships with Merck, Drs Reardon, Shih, and Wen did not write the recommendations and narratives addressing temozolomide and were recused from consensus voting on these recommendations. Because of relationships with Genentech, Drs Reardon, Wen, and Kirkpatrick did not write the recommendations and narratives regarding bevacizumab and were recused from voting on these recommendations. No other disclosures were viewed as affecting guideline content.
Supplementary material for this article (http://dx.doi.org/10.1016/j.prro.2016.03.007) can be found at www.practicalradonc.org.